Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
about
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
P2860
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@en
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@nl
type
label
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@en
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@nl
prefLabel
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@en
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@nl
P2093
P2860
P356
P1433
P1476
Ristocetin-induced platelet ag ...... in CLL treated with ibrutinib.
@en
P2093
A Hauswirth
C Einberger
C-M Wendtner
E Porpaczy
I Pabinger
L Kazianka
P2860
P2888
P304
P356
10.1038/LEU.2016.316
P577
2016-12-02T00:00:00Z
P6179
1015144178